SYNDIVIA
Syndivia is a biotechnology company. Syndivia's vision is to deliver the best treatment to cancer patients by harnessing unique properties of tumour hallmarks and microenvironment.
SYNDIVIA
Industry:
Biotechnology Health Care Medical
Founded:
2014-01-01
Address:
Illkirch, Alsace, France
Country:
France
Website Url:
http://www.syndivia.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
3.05 M EUR
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro SPF Google Tag Manager Google Analytics Content Delivery Network LetsEncrypt SSL By Default Font Awesome
Similar Organizations
Atugen
A biotechnology company based in Berlin, Germany.
Boditech Med
Boditech Med is a biotechnology company based in Chuncheon.
Cellectis
Cellartis AB is a biotechnology company based in Sweden.
fasteris
Fasteris is a Swiss biotechnology company based in Geneva.
Geneius
Geneius is a Biotechnology company.
Mucosis
Mucosis is a clinical stage Dutch biotechnology company developing mucosal vaccines.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
Current Employees Featured
Founder
Investors List
Bpifrance
Bpifrance investment in Venture Round - Syndivia
Cap Innov'Est
Cap Innov'Est investment in Seed Round - Syndivia
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - Syndivia
Official Site Inspections
http://www.syndivia.com Semrush global rank: 1.94 M Semrush visits lastest month: 11.04 K
- Host name: 198.49.23.144
- IP address: 198.49.23.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Syndivia"
Syndivia – Making a difference in ADC with GeminiMab™ and …
At Syndivia, we are dedicated to advancing treatment options for cancer patients through our innovative GeminiMab™ Technology. This platform enables the creation of site-specific …See details»
Syndivia - Crunchbase Company Profile & Funding
Organization. Syndivia . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Syndivia is a biotechnology company based in …See details»
About - Syndivia
©[YEAR] Syndivia, 8 Allée Gaspard Monge, ISIS, Strasbourg, Grand Est, 67083, France [email protected] [email protected]See details»
Syndivia 2025 Company Profile: Valuation, Funding & Investors
When was Syndivia founded? Syndivia was founded in 2014. Where is Syndivia headquartered? Syndivia is headquartered in Strasbourg, France. What is the size of Syndivia? Syndivia has 6 …See details»
Syndivia Company Profile - Office Locations, Competitors ... - Craft
Syndivia is a biotechnology company that develops treatment solutions to cancer patients by leveraging microenvironment and anatomical hallmarks for tumors. It provides APN technology …See details»
Syndivia - Funding, Financials, Valuation & Investors - Crunchbase
Syndivia is a biotechnology company based in France. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. ... How much funding has this organization raised …See details»
Team — Syndivia
©[YEAR] Syndivia, 8 Allée Gaspard Monge, ISIS, Strasbourg, Grand Est, 67083, France [email protected] [email protected]See details»
Syndivia Overview | SignalHire Company Profile
Syndivia is a private company that has been in the industry for 10 years. The company currently specializes in the Biotechnology, Biotechnology areas. The position of the Co-Founder & CEO …See details»
Syndivia Company Information - Funding, Investors, and More
The company Syndivia has raised a total of $2.3m in funding over 1 rounds. Key Insights: Syndivia , March 2020: $2.3m; 2020. Syndivia , March 2020 $2.3m. Industries. Syndivia is …See details»
SYNDIVIA - VentureRadar
Syndivia is a biotechnology company that is developing a pipeline of targeted therapies for solid cancers by leveraging a specific targeting of the tumor microenvironment and anatomical …See details»
Syndivia SAS - Drug pipelines, Patents, Clinical trials - Synapse
STRASBOURG, France, Nov. 16, 2023 /PRNewswire/ -- Syndivia, a leading biotechnology company at the forefront of innovative DAR1 ADCs (antibody-drug conjugates with a drug-to …See details»
SYNDIVIA Company Profile | STRASBOURG, GRAND EST, France
Find company research, competitor information, contact details & financial data for SYNDIVIA of STRASBOURG, GRAND EST. Get the latest business insights from Dun & Bradstreet.See details»
Syndivia - euroquity.com
About your organization Syndivia is a biotechnology company focused on the development of next-generation targeted therapies for cancer treatment. The company unites leading experts …See details»
Syndivia - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Syndivia . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 2. About. Syndivia has 2 …See details»
PRESS RELEASE Syndivia In-Licenses DARx Technology for 1-to-1 …
* Organization for accelerating tech transfer About Syndivia Syndivia is a research-driven biotechnology company that is developing a pipeline of targeted therapies for solid cancers by …See details»
News - Syndivia
Nov 16, 2023 News & Press Archive. STRASBOURG, France, March 10, 2020 – Syndivia, a research-driven biotechnology company focused on the development of new therapeutic …See details»
Syndivia Raises €1M Investment to Advance Its Tumour …
Dec 10, 2019 Syndivia is a company that is developing a platform for the targeted therapy of solid cancers by leveraging a unique microenvironment and anatomical hallmarks of these …See details»
Vision - Syndivia
At Syndivia, we are dedicated to advancing treatment options for cancer patients through our innovative GeminiMab™ Technology. This platform enables the creation of site-specific …See details»
Syndivia In-Licenses DARx Technology for 1-to-1 Linkage of …
Jan 28, 2020 For more information, visit https://www.syndivia.com. Media Contact. Syndivia Sasha Koniev – CEO Phone: 00 33 3 67 10 42 20 Email: [email protected] Related Files. PR …See details»
Pipeline - Syndivia
2017: Out-licensing agreement established with Inatherys, limited to one target (CD71). The ADC is currently undergoing phase I/IIa clinical trial (NCT03957915). 2022: Auricula Biosciences co …See details»